Vitalhub (TSX: VHI) reported a 33% year-over-year revenue increase to $31.7 million for the second quarter of 2026. The company crossed a significant operational threshold, closing June with $101.5 million in annual recurring revenue (ARR), representing 10% organic growth over the prior year.

The financial performance was underpinned by strong recurring revenue streams, which accounted for $24.5 million, or 77% of total revenue. This segment includes term license, maintenance, and support fees. Virtual care term license revenue contributed $2.3 million, while perpetual license revenue stood at $800,000. Services, hardware, and other revenue reached $4.1 million, up from $2.7 million in the same period last year.

Financial Metrics and Margins

Adjusted EBITDA for the quarter was $8.2 million, maintaining a margin of 26%. This compares to adjusted EBITDA of $6.3 million in the prior year period, which also carried a 26% margin. Gross margin contracted slightly to 79% of revenue, down from 81% in the previous year. Management attributed the gross margin variance partly to timing mismatches in services revenue recognition, where expenses were incurred before specific milestones allowed for corresponding revenue recognition.

*Prior year revenue derived from current year figure and stated growth rate.

What the Numbers Show

The stability of the adjusted EBITDA margin at 26% despite a 33% surge in revenue indicates effective operating leverage following the integration of Induction and Novari. While gross margins dipped two percentage points due to services revenue timing, the absolute EBITDA growth outpaced revenue growth proportionally, suggesting that fixed costs are being spread over a larger top line. The company’s cash position increased by over $15 million during the quarter, reinforcing its ability to fund further M&A without debt.

Balance Sheet and Capital Allocation

Vitalhub ended the quarter with $136.5 million in cash and investments, carrying no debt. The cash balance grew by more than $15 million during the quarter, driven by collection activity and platform integration synergies. Subsequent to quarter-end, the company completed the acquisition of Buddy Healthcare. Post-transaction, Vitalhub retains over $120 million in cash for future deployment.

Management has initiated a normal course issuer bid (NCIB) to repurchase shares, balancing capital allocation between buybacks and M&A. CEO Dan Matlow noted that while buybacks are active, M&A remains the primary focus for long-term shareholder return. The pro forma ARR as of June 30, 2026, including Buddy Healthcare, would have been approximately $106 million.

Operational Updates and Market Challenges

Growth drivers included contributions from Zesty, Strata, and Novari products. However, the UK market faced headwinds due to customer suspensions linked to the NHS’s Palantir contract situation. Some System Control Centres paused usage pending outcomes regarding the Federal Department of Public Health (FDP) and Palantir-based solutions. A break clause in the national Palantir contract is set for Q1 2027, with parliamentary indications suggesting potential removal of the product, which management views as an opportunity for its SHREWD product.

On the technology front, Vitalhub introduced AI-driven protocoling solutions within the Novari product and is developing transcription services for community care. These AI initiatives are expected to begin contributing to revenue streams by the end of 2027. The Ontario Health deal continues to ramp up, adding between $500,000 and $1 million quarterly to ARR growth.

VitalHub Corp. reported second-quarter earnings per share of $0.03, missing the analyst consensus estimate of $0.05 by 40 percent. While the Toronto-based health and human services software provider saw total revenue rise 33% year-over-year to $31.738 million, this figure also missed the $32.293 million sales estimate by 1.72 percent. The earnings result was unchanged from the same period last year, signaling a divergence between top-line growth and profitability expectations despite the company’s Annual Recurring Revenue (ARR) crossing the $100 million threshold for the first time.

The company filed its Interim Condensed Consolidated Financial Statements with Canadian securities authorities. VitalHub’s Board approved the financial results, which highlight a strategic shift toward converting adjusted EBITDA into operating cash flow. The filing details the integration of recent acquisitions and improved operational efficiency, even as the company navigated margin pressures. The missed estimates underscore the challenges in translating rapid revenue growth into immediate earnings beats, particularly amidst aggressive expansion strategies.

Financial Performance Highlights

Revenue for the quarter reached $31,737,512, up from $23,857,548 in the equivalent prior year period. Gross profit as a percentage of revenue was 79% in Q2 2026, compared to 81% in the prior year. Net income before income taxes increased 62% to $3,644,002 from $2,255,226. EBITDA surged 83% to $6,571,464 from $3,599,683. Adjusted EBITDA, a non-IFRS measure used by management to evaluate cash flows, reached $8,162,917 or 26% of revenue, compared to $6,304,647 or 26% of revenue in the prior year.

ARR Growth and Acquisition Strategy

ARR as at June 30, 2026, stood at $101,533,157, an increase of 28% from $79,589,081 in the same period last year. The year-over-year ARR movement was attributable to organic growth of $8,124,613 (10%), acquisition growth of $12,000,000 (15%), and foreign exchange gains of $1,819,463. Quarter-over-quarter, ARR increased by 2% to $101,533,157 from $99,078,809 at March 31, 2026, driven by organic growth of $1,802,495 and foreign exchange gains of $651,853.

Subsequent to the quarter-end, VitalHub completed the acquisition of Buddy Healthcare Ltd Oy. on July 10, 2026. The total closing consideration was approximately $13.4 million (€8.3 million) in cash, subject to a 10% escrow for nine months, plus the issuance of 75,000 common shares of VitalHub. This acquisition expands VitalHub’s patient journey optimization capabilities and its footprint across the Nordic region in Europe. With this addition, the company’s pro forma ARR as at June 30, 2026, would have been approximately $106.0 million.

What the Numbers Show

The divergence between top-line revenue growth and margin performance warrants attention. While revenue surged 33%, gross profit margin contracted slightly from 81% to 79%. However, adjusted EBITDA margin remained stable at 26%, indicating that operating leverage is offsetting gross margin pressure through disciplined cost management. The significant rise in amortization of intangible assets—up 126% to $3,246,005 from $1,437,740—reflects the impact of recent acquisitions on the income statement, though this is excluded from adjusted EBITDA. The company’s cash position strengthened to $136,508,574 as at June 30, 2026, from $119,180,625 at December 31, 2025, providing ample liquidity for further M&A activity.